Haleon plc (NYSE:HLN) Shares Bought by Van ECK Associates Corp

Van ECK Associates Corp grew its position in Haleon plc (NYSE:HLN) by 13.5% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 3,509,400 shares of the company’s stock after buying an additional 418,609 shares during the quarter. Van ECK Associates Corp’s holdings in Haleon were worth $33,480,000 at the end of the most recent quarter.

A number of other hedge funds have also made changes to their positions in HLN. CWM LLC increased its position in shares of Haleon by 13.6% in the third quarter. CWM LLC now owns 24,978 shares of the company’s stock valued at $264,000 after buying an additional 2,996 shares in the last quarter. Ritholtz Wealth Management purchased a new stake in Haleon during the 3rd quarter worth about $275,000. Creative Planning increased its position in Haleon by 15.2% during the 3rd quarter. Creative Planning now owns 285,227 shares of the company’s stock worth $3,018,000 after purchasing an additional 37,566 shares in the last quarter. Bleakley Financial Group LLC purchased a new stake in Haleon during the 3rd quarter worth about $126,000. Finally, Aaron Wealth Advisors LLC increased its position in Haleon by 23.8% during the 3rd quarter. Aaron Wealth Advisors LLC now owns 29,374 shares of the company’s stock worth $311,000 after purchasing an additional 5,639 shares in the last quarter. Hedge funds and other institutional investors own 6.67% of the company’s stock.

Haleon Stock Down 2.5 %

Shares of NYSE:HLN opened at $9.71 on Friday. The stock’s 50-day moving average price is $9.54 and its two-hundred day moving average price is $9.80. The company has a current ratio of 0.84, a quick ratio of 0.58 and a debt-to-equity ratio of 0.44. Haleon plc has a 12-month low of $7.89 and a 12-month high of $10.80. The firm has a market cap of $43.93 billion, a price-to-earnings ratio of 28.54, a PEG ratio of 2.70 and a beta of 0.28.

Analyst Ratings Changes

A number of analysts recently commented on HLN shares. Morgan Stanley cut Haleon from an “overweight” rating to an “equal weight” rating in a research report on Friday, January 10th. Sanford C. Bernstein cut Haleon from an “outperform” rating to a “market perform” rating in a research report on Wednesday, January 8th. Three research analysts have rated the stock with a hold rating, three have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $10.95.

Haleon Company Profile

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.